A test tube is seen in front of displayed Biogen logo in this illustration taken on, December 1, 2021. Dado Ruvic | Reuters Biogen on Wednesday reported first-quarter profit that topped estimates as the company’s cost-cutting efforts took hold and sales of its closely watched Alzheimer’s drug, Leqembi, came in higher than expected. Biogen and … Read more
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.) Markets up: The S & P … Read more
Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval. AJ Mast | Bloomberg | Getty … Read more
Good afternoon! The launch of the closely watched Alzheimer’s drug Leqembi is off to a slow start. Still, demand for the treatment from Biogen and its Japanese partner Eisai is rising. That’s the update the two drugmakers gave Wall Street during their latest quarterly earnings calls earlier this month. But before we get into the numbers, … Read more
Biogen on Tuesday reported fourth-quarter revenue and profit that shrank from a year ago, as it recorded charges related to dropping its controversial Alzheimer’s drug Aduhelm and as sales slumped in its multiple sclerosis therapies, the company’s biggest drug category. Biogen booked sales of $2.39 billion for the quarter, down 6% from the same period a … Read more
1. Record run Here are the most important news items that investors need to start their trading day: The S&P 500 closed above 5,000 on Friday for the first time as U.S. stocks continued their steady climb. The S&P, Dow Jones Industrial Average and Nasdaq have all risen for five straight weeks. A slate of … Read more
The Biogen headquarters in Cambridge, Massachusetts, on Oct. 24, 2023. Vanessa Leroy | Bloomberg | Getty Images Biogen on Wednesday said it will discontinue the sale and development of its older and highly controversial Alzheimer’s drug Aduhelm to refocus the company’s efforts to treat the memory-robbing disease. The biotech company will focus on rolling out … Read more
As the old Wall Street adage goes, health care tends to underperform the stock market in presidential election years — and in recent cycles, that’s been true. But, there’s reason to believe this year that many health-related stocks, led by Eli Lilly , could defy historical convention. The S & P 500 Health Care Sector … Read more
Investor optimism for Eli Lilly ‘s diabetes and obesity treatments in 2023 lifted the stock to its seventh annual gain in a row. In the new year, it should be the same old story. Shares of Eli Lilly have taken a breather over the past three months, as investors book profits in the top performer … Read more
Soumyabrata Roy | Nurphoto | Getty Images Drugmakers are closing out a year when they achieved several historic firsts that will shape the pharmaceutical industry in 2024 and beyond. The weight loss drug market transformed into the pharmaceutical industry’s newest gold rush this year, as demand for costly but highly effective treatments from Novo Nordisk … Read more
/cdn.vox-cdn.com/uploads/chorus_asset/file/25378907/STK088_SPOTIFY_CVIRGINIA_C.jpg)
